Research Update

Deltex Medical Group PLC
06 July 2005


                            Deltex Medical Group plc


      CardioQTM delivers excellent results in colorectal surgery patients


6 July 2005:  Deltex Medical Group plc ('Deltex Medical' and the 'Company'),
today announces further details of the results of a double-blinded prospective
randomised controlled clinical trial using its CardioQTM haemodynamic
monitoring system on colorectal patients during their operations.


The trial was undertaken by surgeons and anaesthetists at the Freeman Hospital
in Newcastle-upon-Tyne.  In the study, the control group were given fluids
intra-operatively at the anaesthetist's discretion whereas the treatment group
were given fluids based on an algorithm guided by the CardioQTM.  Additional
results to those previously announced were presented in Dublin today at the
Tripartite Colorectal Meeting (a clinical meeting for colorectal surgeons from
the UK, USA and Australia).


The study showed that patients treated with the CardioQTM were able to tolerate
a full diet after two rather than four days and were independently assessed as
fit for discharge from hospital after six rather than nine days.  Previously
announced results showed that the CardioQTM patients were actually discharged
from hospital after seven days and that they suffered considerably fewer
post-operative complications.


Deltex Medical's Chief Executive, Andy Hill commented:


'The Association of Coloproctology of Great Britain & Ireland produced a report
in June 2004 following the results of its audit of bowel cancer treatments in 93
NHS hospitals.  The average length of hospital stay was over twelve days, with
only six hospitals achieving lengths of stay of under ten days and not one of
them doing as well as the CardioQTM patients at the Freeman.'


The same report identified average mortality within thirty days of bowel cancer
surgery of 6%.  None of the 54 CardioQTM patients at the Freeman died; likewise,
none of the 64 CardioQTM patients from a similar 2004 study at Worthing hospital
died.'



For further information, please contact:-


Deltex Medical Group plc                                           01243 774 837

Nigel Keen, Chairman                                  Andy Hill, Chief Executive
Ewan Phillips, Finance Director


Financial Dynamics                                                 0207 831 3113

David Yates
Lucy Briggs


Notes for Editors

Deltex Medical manufactures and markets the CardioQTM monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQTM, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQTM incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQTM provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.



There are already over 1,250 CardioQTMs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
TM which have repeatedly:-


  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works


  • proved that the CardioQTM works in a wide range of surgical procedures


  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange                    W